Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.

Authors :: Strand, Vibeke
de Vlam, Kurt
Covarrubias-Cobos, Jose A.
Mease, Philip J.
Gladman, Dafna D.
Linda Chen
Kudlacz, Elizabeth
Wu, Joseph
Cappelleri, Joseph C.
Hendrikx, Thijs
Ming-Ann Hsu
Source :: RMD Open; 1/11/2019, Vol. 5, p1-11, 11p
Publication Year :: 2019

Full Text Access

Tools